Rapport Therapeutics, Inc. Common Stock
$37.65
+7.9%Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -13.2).
Valuation inputs: P/E -13.2, earnings yield N/A, momentum +7.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -23.0%, ROIC -25.2%).
Profitability stack: net margin 0.0%, ROE -23.0%, ROIC -25.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +5.4%, momentum +7.9%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Rapport Therapeutics, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Rapport Therapeutics, Inc. Common Stock Fair Value Envelope
No Revenue Data
RAPP has not reported any revenue values in the available annual periods.
Rapport Therapeutics, Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
RAPP has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
RAPP has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
RAPP has not reported any net profit margin values in the available annual periods.
Rapport Therapeutics, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Neutral working capital impact. Changes in current assets and liabilities balanced out.
Rapport Therapeutics, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Rapport Therapeutics, Inc. Common Stock Street Expectations Map
Wall Street analysts project that RAPP stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 54.00, with estimates ranging from a low of 40.00 to a high of 66.00.
The consensus 1-year price target stands at 54.00, with estimates ranging from a low of 40.00 to a high of 66.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Rapport Therapeutics, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have sold $37.94M worth of RAPP shares, with no buying activity reported.
3 Months
0
0.00
912.4K
36.41M
-36.4M
-$36.41M
3-6 Months
0
0.00
39.3K
1.12M
-1.1M
-$1.12M
6-9 Months
0
0.00
15.2K
410.59K
-411K
-$411K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Third Rock Ventures V, L.P.
10 Percent Owner
$34.39M
Yeleswaram Krishnaswamy
Officer: Chief Development Officer
$1.91M
Bredt David
Officer: Chief Scientific Officer
$842K
Gault Cheryl
Officer: Chief Operating Officer
$410K
Ceesay Abraham
Director, Officer: Chief Executive Officer
$395K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $37.94M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
RAPP has not reported any dividend yield values in the available annual periods.
rapp Dividend History
Learning Layer
Related Guides
Build conviction on RAPP by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.